We previously reported a phase I clinical trial of a peptide vaccine ring finger protein 43 (RNF43) and 34-kDa translocase of the outer mitochondrial membrane 
We previously reported a phase I clinical trial of a peptide vaccine ring finger protein 43 (RNF43) and 34-kDa translocase of the outer mitochondrial membrane improves adjuvant treatment of colon cancer. 2, 3 In Japan, however, some specialists are skeptical of L-OHP as an adjuvant treatment for stage III colon cancer because of better outcomes in Japanese randomized trials than those in Western countries and cumulative neurotoxicity risk with L-OHP-based therapy. [4] [5] [6] We previously reported a phase I clinical trial of a peptide vaccine ring finger protein 43 (RNF43) and 34-kDa translocase of the outer mitochondrial membrane (TOMM34) combined with uracil-tegafur (UFT)/LV for patients with metastatic CRC, and demonstrated the safety and immunological responsiveness of this combination therapy. [7] [8] [9] In this study, we evaluated vaccination- 
| Study design
Detailed information of the study design was described previously. 
| Enzyme-linked immunospot assay
Peptide-specific CTL responses were estimated by the in vitro enzyme-linked immunospot (ELISPOT) assay as previously described. 14 
| Statistical analyses
Survival curves were plotted using the Kaplan-Meier method and compared with the log-rank test. Survival was measured from the first vaccination until recurrence, death or the last follow-up. Tests were always 2-sided; P < .05 was considered significant. Statistical analyses were performed using JMP 11 software (SAS Institute, Cary, NC, USA).
3 | RESULTS
| Demographics
The patient flow diagram is shown in were not evaluated (Table 3) . 
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